Up to 45 Patients aged 12 to 39 with osteosarcoma (bone cancer) that had recurred in the
lungs and has recently been surgically removed will be enrolled. Patients will receive
OST31-164 infusions every 3 weeks over 48 weeks and be followed after that for 3 years.